Source: International Congress 2016 – Prognostic variables in lung cancer I
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Jorge Moisés Lafuente (Barcelona, Spain), Jorge Moisés Lafuente, Sandra Santasusagna, Alfons Navarro, Nuria Viñolas, Josep Ramirez, Laureano Molins, Carlos Agustí, Jeisson Osorio, Adela Saco, Marc Ruiz, Joan Castellano, Anna Cordeiro, Carmen Muñoz, Mariano Monzo, Ramón Marrades. NKX2-1 impacts prognosis in early stage NSCLC not harboring TP53 mutations. Eur Respir J 2016; 48: Suppl. 60, 2858

Member's Comments

No comment yet.

Related content which might interest you: Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012 The NANCI lncRNA-NKX2-1 gene duplex impacts prognosis in stage I NSCLC. Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018 Frequency and clinical-tomographic characterization of NSCLC with T790M mutation to TKI progression. Source: International Congress 2019 – Diagnosis of lung cancer Year: 2019 Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 Arg72Pro P53 gene polymorphism is associated with P53 mutations in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004 EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype Source: Eur Respir J 2014; 43: 872-883 Year: 2014 Very early detection of small clones harbouring EGFR mutations in NSCLC by 2nd generation sequencing Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients Source: Eur Respir Rev 2014; 23: 390-392 Year: 2014 EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Frequency of T790M substitution in exon 20 of EGFR gene in brain metastases in chemotherapy-naive non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 Arg72Pro P53 gene polymorphism as a predisposing factor for non-small cell lung cancer (NSCLC) development Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004 Overall survival analysis and characterization of an EGFR mutated non small cell lung cancer (NSCLC) population Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 Model for predicting EGFR mutation status in lung cancer Source: Breathe, 15 (4) 340; 10.1183/20734735.0250-2019 Year: 2019 BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer Source: Eur Respir J 2002; 19: 134-140 Year: 2002 The correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011